Access to anti-retroviral drugs, female in Sweden

Sweden: Access to anti-retroviral drugs, female was 96.0% in 2022. ▲ Rising

Latest (2022)
96.0%
Change on year
up 1.1%
World rank
14th
of 141 countries
All-time high
97.0%
in 2019
All-time low
24.0%
in 2000
Years of data
23
2000–2022

Access to anti-retroviral drugs, female in Sweden, 2000–2022

204060801002000201120222000: 24 %2001: 25 %2002: 27 %2003: 33 %2004: 37 %2005: 39 %2006: 44 %2007: 54 %2008: 65 %2009: 71 %2010: 77 %2011: 80 %2012: 83 %2013: 87 %2014: 91 %2015: 93 %2016: 95 %2017: 96 %2018: 96 %2019: 97 %2020: 96 %2021: 95 %2022: 96 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2022, access to anti-retroviral drugs, female in Sweden stood at 96.0%.

Compared with earlier readings it is up 1.1% on the previous year and up 15.7% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Sweden peaked at 97.0% in 2019 and was at its lowest, 24.0%, in 2000.

That places Sweden 14th out of 141 countries with data for 2022, putting it in the top 10%.

The long-run direction has been consistently rising across the 23 years of available data.

Access to anti-retroviral drugs, female in Sweden, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Sweden, 2000 to 2022.
Year % Change
2000 24.0%
2001 25.0% +4.2%
2002 27.0% +8.0%
2003 33.0% +22.2%
2004 37.0% +12.1%
2005 39.0% +5.4%
2006 44.0% +12.8%
2007 54.0% +22.7%
2008 65.0% +20.4%
2009 71.0% +9.2%
2010 77.0% +8.5%
2011 80.0% +3.9%
2012 83.0% +3.8%
2013 87.0% +4.8%
2014 91.0% +4.6%
2015 93.0% +2.2%
2016 95.0% +2.2%
2017 96.0% +1.1%
2018 96.0% +0.0%
2019 97.0% +1.0%
2020 96.0% -1.0%
2021 95.0% -1.0%
2022 96.0% +1.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 41.9% 24.0% 71.0% 10
2010s 89.5% 77.0% 97.0% 10
2020s 95.7% 95.0% 96.0% 3

Countries ranked near Sweden

  1. 12 Rwanda 97.0% compare
  2. 12 United Arab Emirates 97.0% compare
  3. 14 Liberia 96.0% compare
  4. 14 Togo 96.0% compare
  5. 14 United Kingdom of Great Britain and Northern Ireland 96.0% compare
  6. 14 Zambia 96.0% compare

See the full ranking of 160 places →

More gender data for Sweden

All data for Sweden →

Frequently asked questions

What is access to anti-retroviral drugs, female in Sweden?
Access to anti-retroviral drugs, female in Sweden was 96.0% in 2022, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Sweden?
The highest recorded value was 97.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Sweden?
The lowest recorded value was 24.0% in 2000.
How does Sweden rank for access to anti-retroviral drugs, female?
Sweden ranks 14th out of 141 countries with data for 2022.
Is access to anti-retroviral drugs, female rising or falling in Sweden?
Over the last ten years it is up 15.7%. The long-run trend across the full record is rising.
Where does this Sweden data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 23 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Sweden. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/sweden/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/sweden/">Access to anti-retroviral drugs, female in Sweden</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.